Published in Cancer Weekly, April 10th, 2006
According to recent research published in the journal Blood, "Relapse is a major obstacle in the cure of AML. The Pediatric Oncology Group AML Study 9421 tested 2 different strategies to improve event-free survival (EFS) and overall survival (OS)."
"Patients were randomized to receive standard-dose DAT or high-dose DAT during induction," explained D. Becton and colleagues, Stanford University. "To interfere with P-glycoprotein (P-g p)-dependent drug efflux, the second...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.